Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 13/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 10/20 | 0.65 |
| ▸ | COQ8A | Q8NI60 | 9/20 | 0.65 |
| ▸ | NLK | Q9UBE8 | 9/20 | 0.65 |
| ▸ | EPHB6 | O15197 | 3/20 | 0.65 |
| ▸ | ABL1 | P00519 | 3/20 | 0.65 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.65 |
| ▸ | STK16 | O75716 | 1/20 | 0.65 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880678 | 1.00 | GAK (0.65) | GAKRIPK2COQ8ANLKEPHB6 | |
| Hydrochloric Acid SCHEMBL2291538 | 0.99 | GAK (0.64) | GAKRIPK2COQ8ANLKEPHB6 | |
| SCHEMBL30880616 | 0.91 | GAK (0.73) | GAKRIPK2COQ8ANLKEPHB6 | |
| SCHEMBL14035048 | 0.87 | RIPK2 (0.56) | GAKRIPK2COQ8ANLKEPHB6 | |
| SCHEMBL30880714 | 0.86 | GAK (0.65) | GAKRIPK2COQ8ANLKEPHB6 | |
| SCHEMBL14035007 | 0.86 | GAK (0.54) | GAKRIPK2COQ8ANLKEPHB6 | |
| SCHEMBL30880470 | 0.86 | GAK (0.65) | GAKRIPK2COQ8ANLKEPHB6 | |
| SCHEMBL2292717 | 0.84 | GAK (0.60) | GAKRIPK2COQ8ANLKEPHB6 | |
| SCHEMBL30880543 | 0.84 | HTT (0.66) | GAKRIPK2COQ8ANLKKDR | |
| SCHEMBL30880591 | 0.81 | GAK (0.59) | GAKRIPK2COQ8ANLKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| EP-2152672-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MAP4K2, MAP3K20, MAP3K2 | GAK 231/4885RIPK2 349/4885COQ8A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.